The US Department of HHS is awarding the pharmaceutical company Moderna $590 million to continue developing a vaccine to protect against bird flu.

Summit Therapeutics has soared due to hopes around its cancer drug candidate, ivonescimab. It outperformed Keytruda in a phase 3 trial for treating advanced non-small cell lung cancer. Investors ...

We recently published a list of These 10 Stocks Were Wednesday’s Worst Performers. In this article, we are going to take a ...

Fintel reports that on January 29, 2025, Goldman Sachs downgraded their outlook for Moderna (NasdaqGS:MRNA) from Buy to ...

Delving into the details, we found 51% of traders were bullish, while 25% showed bearish tendencies. Out of all the trades we ...

The number of bird flu cases in Central Massachusetts is relatively low, compared to a swath of the state that runs from ...